It’s been a buzzy few years for prescription digital therapeutics, marked by bankruptcies, reimbursement policy changes and AI advancements.
At their best, DTx solutions can offer a more personalized, convenient and cost-effective care experience. But barriers to adoption remain. What are they, and what’s being done about them? Senior Writer Anastassia Gliadkovskaya explores these questions with Joseph Perekupka, CEO of Freespira, and Andy Molnar, SVP of industry affairs for the American Telemedicine Association.
To learn more about the topics in this episode:

The TEAM model arrives, ready or not
21:09

Cutting employer costs by steering patients to top docs
24:51

A Fierce federal health policy checkup
30:22